CorMedix delivered its strongest financial quarter to date, bolstered by the transformational acquisition of Melinta Therapeutics, driving record revenue and substantial EBITDA growth.

• Achieved record revenue of $104.3 million and net income of $108.6 million, significantly enhancing financial performance.
• Raised full year revenue guidance from $375 million to a range of $390 million to $410 million, reflecting strong market momentum.
• Announced a strategic minority investment in Talphera Inc., positioning CorMedix for expansion into critical care.
• Integration of Melinta operations ahead of schedule, with expected synergies of $30 million from a total of $35-$45 million by late 2025.
• Upcoming catalysts include pivotal Phase III data for Rezzayo in invasive fungal infection prophylaxis and expansion of DefenCath to prevent CLABSI in TPN patients.